Once again, blarcamesine prophylaxis.
The use of blarcamesine as a CNS (or other) prophylactic, a drug that will prevent the onset of a disease before any symptoms ever appear, has been discussed. For a few, even mentioning the possibility of this is regarded as “pumping.” Should that be your perspective, read no further. The following is too much for you. Stay safe. Click off to the next posting.
Yes, clearly, if blarcamesine or any of the other Anavex sigma-1 receptor activators prove to provide prophylactic functions, their use to prevent, not just treat various CNS diseases will be massive. Dr. Missling himself tangentially alluded to this possibility. Dr. Randi Hagerman, a world-class CNS disease researcher stated that she’d like to take blarcamesine prophylactically.
The biological consideration must be this. If blarcamesine is proven (in the Phase 3 clinical trials) to stop or reverse the progression of Parkinson’s disease dementia, Parkinson’s disease, and/or Alzheimer’s disease, what could be the biological mechanism that would prevent the drug from stopping the progression of any of those diseases at their very earliest, pre-symptomatic stages?
If the drug can successfully treat those CNS diseases after they’ve developed and set in, with detectable symptoms, there is no biological or chemical reason those diseases would not also be stopped at their earliest stages, before symptoms ever appear. That would be prophylaxis; prevention.
A good number of postings have told of new methods to detect Alzheimer’s and other CNS disease vulnerabilities before those diseases ever appear. Presently, their only utility will be to allow people who are thereby destined to suffer to prepare for that suffering. Presently there are no really useful drugs for Parkinson’s or Alzheimer’s.
But, in a few years, after blarcamesine is approved to treat Parkinson’s and Alzheimer’s, how will those new CNS disease vulnerability tests be used? Will it be A, or B?
A. “Mrs. Smith, we’ve detected that you are destined to suffer and die from Alzheimer’s disease. But fortunately, there’s the new drug blarcamesine that can stop the disease’s progression after it sets in. We'll just watch and wait. When you start to get symptoms, we’ll get you on the drug right away.”
Or,
B. “Mrs. Smith, your test results came back. Sooner or later, you are destined to get Alzheimer’s. Therefore, let’s get you on blarcamesine right away, so you can continue to live normally. It will prevent the onset of even the mildest Alzheimer’s symptoms. Here’s your prescription.”
Fact is, sigma-1 activation by blarcamesine facilitates, modulates normalized homeostatic processes. With those, cells function normally, healthfully. Yet to be shown in human trials, but there is a strong probability that because of its facilitation of cellular homeostatic processes (there are many), blarcamesine (perhaps even better, Anavex 3-71) will prove to be useful anti-aging agents.
Presently, there is no evidence precluding such. Most significantly, the Anavex molecules are profoundly safe; do not produce side effects or adverse events of any endurance or consequence.
As I’ve claimed before, Missling has had someone, in house (proprietary info) conduct a variety of standard aging studies on organisms using blarcamesine. First would be to have Caenorhabditis elegans nematodes swim around and live and reproduce in water with blarcamesine, compared to the same C. elgans organisms in an adjacent tank without blarcamesine. C. elegans is one of the most commonly used and well-characterized organisms used in aging studies. Missling surely has data from them. Standard stuff; gained in short-term studies. Nematodes live and die fast, compared to vertebrates.
Other organisms are used in aging studies; I won’t list them out. But they all have neurons and cells with sigma-1 receptor proteins, which modulate homeostatic and other cellular processes.
Mechanistically, aging prophylaxis by blarcamesine is quite probable. Sooner or later, we’ll learn of preclinical studies.
None of the above has prompted my accumulation of Anavex shares. No need for that. Blarcamesine’s safety and efficacies for the targeted CNS diseases is sufficient. But those won’t be the end of the Anavex story. Lots yet still ahead.
